These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The Case ∣ Hyperbicarbonatemia in a patient with Waldenstrom's macroglobulinemia. Pseudohyperbicarbonatemia due to paraproteinemia. Krish P; Jhaveri KD Kidney Int; 2012 Mar; 81(6):603-5. PubMed ID: 22373713 [No Abstract] [Full Text] [Related]
4. Improvement of the thermal amplitude after rituximab treatment for cold agglutinin disease with Waldenström's macroglobulinemia. Hattori N; Ishii N; Ariizumi H; Adachi D; Matsuda I; Nakamaki T; Tomoyasu S Ann Hematol; 2010 Jan; 89(1):103-4. PubMed ID: 19513714 [No Abstract] [Full Text] [Related]
5. Waldenstrom's macroglobulinaemia: to treat or not to treat? Sundriyal D; Kumar N; Kotwal S; Shirsi N BMJ Case Rep; 2014 Nov; 2014():. PubMed ID: 25414220 [TBL] [Abstract][Full Text] [Related]
7. Successful treatment with Rituximab and Bendamustine in a patient with newly diagnosed Waldenström's Macroglobulinemia complicated by Bing-Neel syndrome. Varettoni M; Marchioni E; Bonfichi M; Picchiecchio A; Arcaini L; Arbasino C; Gotti M; Da Vià M; Delmonte M; Sciarra R; Cazzola M Am J Hematol; 2015 Aug; 90(8):E152-3. PubMed ID: 25975811 [No Abstract] [Full Text] [Related]
9. Novel agents in the treatment of Waldenström's macroglobulinemia. Treon SP; Hatjiharissi E; Leleu X; Moreau AS; Roccaro A; Hunter ZR; Soumerai JD; Ciccarelli B; Xu L; Sacco A; Ngo HT; Jia X; Yang C; Adamia S; Branagan AR; Ho AW; Santos DD; Tournilhac O; Manning RJ; Leduc R; O'Connor K; Nelson M; Patterson CJ; Ghobrial I Clin Lymphoma Myeloma; 2007 Aug; 7 Suppl 5():S199-206. PubMed ID: 17877845 [TBL] [Abstract][Full Text] [Related]
10. Soluble CD27 is a faithful marker of disease burden and is unaffected by the rituximab-induced IgM flare, as well as by plasmapheresis, in patients with Waldenström's macroglobulinemia. Ciccarelli BT; Yang G; Hatjiharissi E; Ioakimidis L; Patterson CJ; Manning RJ; Xu L; Liu X; Tseng H; Gong P; Sun J; Zhou Y; Treon SP Clin Lymphoma Myeloma; 2009 Mar; 9(1):56-8. PubMed ID: 19362974 [TBL] [Abstract][Full Text] [Related]
11. Waldenström's macroglobulinaemia: laboratory diagnosis and treatment. Owen RG; Johnson SA; Morgan GJ Hematol Oncol; 2000 Jun; 18(2):41-9. PubMed ID: 10960874 [No Abstract] [Full Text] [Related]
12. Marked increase in serum IgM during treatment of Waldenstrom's macroglobulinemia with cladribine. Krishna VM; Carey RW; Bloch KJ N Engl J Med; 2003 May; 348(20):2045-6. PubMed ID: 12748329 [No Abstract] [Full Text] [Related]
13. Flare in neuropathy following rituximab therapy for Waldenstrom's macroglobulinemia. Noronha V; Fynan TM; Duffy T J Clin Oncol; 2006 Jan; 24(1):e3. PubMed ID: 16382111 [No Abstract] [Full Text] [Related]
14. Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. Hensel M; Villalobos M; Kornacker M; Krasniqi F; Ho AD Clin Lymphoma Myeloma; 2005 Sep; 6(2):131-5. PubMed ID: 16231851 [TBL] [Abstract][Full Text] [Related]
15. [Pathology, diagnostics, and treatment of Waldenström's macroglobulinaemia]. Holmström MO Ugeskr Laeger; 2011 Oct; 173(41):2557-60. PubMed ID: 21985832 [TBL] [Abstract][Full Text] [Related]
16. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia. Treon SP; Branagan AR; Hunter Z; Santos D; Tournhilac O; Anderson KC Ann Oncol; 2004 Oct; 15(10):1481-3. PubMed ID: 15367407 [TBL] [Abstract][Full Text] [Related]